Table 1 Demographic and clinical characteristics at start of anti-hepatitis C virus (HCV) treatment of chronically HIV/HCV co-infected patients, 1998-2011
Sustained virologic response | ||||
|---|---|---|---|---|
Total | No | Yes | p-value | |
Number of patients (%) | 1309 | 819 (63)a | 490 (37)a | |
Age baseline, years | 42 (38–46) | 42 (38–46) | 42 (37–46) | 0.04 |
Baseline BMI | <0.0001 | |||
< 25 | 329 (25b) | 234 (71) | 95 (29) | |
> =25 | 123 (9) | 96 (78) | 27 (22) | |
Unknown | 857 (66) | 489 (57) | 368 (43) | |
Gender | 0.57 | |||
Male | 960 (73) | 605 (63) | 355 (37) | |
Female | 349 (39) | 214 (61) | 135 (39) | |
HIV transmission route: | 0.05 | |||
Men who have sex with men | 175 (13) | 91 (52) | 84 (48) | |
Male, injection drug use (IDU) | 595 (45) | 393 (66) | 202 (34) | |
Female IDU | 209 (16) | 127 (61) | 82 (39) | |
Male heterosexual | 84 (6) | 55 (65) | 29 (35) | |
Female heterosexual | 96 (7) | 62 (65) | 34 (35) | |
Male other/unknown | 106 (8) | 66 (62) | 40 (38) | |
Female other/unknown | 44 (3) | 25 (57) | 19 (43) | |
Region of origin: | 0.06 | |||
Western | 1101 (84) | 700 (64) | 401 (36) | |
Other | 116 (9) | 72 (62) | 44 (38) | |
Unknown | 92 (7) | 47 (51) | 45 (49) | |
CD4 at baseline (cells/μl) | ||||
0–349 | 264 (20) | 163 (62) | 101 (38) | 0.02 |
350–499 | 306 (23) | 194 (63) | 112 (37) | |
> =500 | 491 (38) | 288 (59) | 203 (41) | |
Missing | 248 (19) | 174 (70) | 74 (30) | |
Nadir CD4 (cells/ μl) | <0.001 | |||
< 200 | 689 (53) | 434 (63) | 255 (37) | |
> =200 | 583 (45) | 381 (65) | 202 (35) | |
Missing | 37 (3) | 4 (11) | 33 (89) | |
HIV RNA levels at baseline (copies/ml) | 0.99 | |||
< =400 | 1082 (83) | 677 (63) | 405 (37) | |
> 400 | 227 (17) | 142 (63) | 85 (37) | |
Hepatitis B virus co-infection | 0.64 | |||
No | 1214 (93) | 762 (63) | 452 (37) | |
Yes | 53 (4) | 30 (57) | 23 (43) | |
Unknown | 42 (3) | 27 (64) | 14 (33) | |
HCV RNA load at baseline | <0.0001 | |||
< 600,000 | 222 (17) | 99 (45) | 123 (55) | |
≥ 600,000 | 724 (55) | 485 (67) | 239 (33) | |
Missing | 363 (28) | 235 (65) | 128 (35) | |
HCV genotypes | <0.0001 | |||
1 | 82 (6) | 53 (65) | 29 (35) | |
1a | 307 (23) | 234 (76) | 83 (27) | |
1b | 147 (11) | 108 (73) | 39 (27) | |
2&3 | 315 (24) | 154 (49) | 161 (51) | |
4 | 143 (11) | 103 (72) | 40 (28) | |
Other/unknown | 315 (24) | 177 (56) | 138 (44) | |
APRIc score: | <0.0001 | |||
< 0.5 | 409 (31) | 206 (50) | 203 (50) | |
0.5–1.5 | 426 (32) | 312 (73) | 114 (27) | |
> =1.5 | 195 (15) | 155 (79) | 40 (21) | |
Unknown | 279 (21) | 146 (52) | 133 (48) | |
Decline in haemoglobin (g/dl) | 0.0017 | |||
No decline | 179 (14) | 126 (70) | 53 (30) | |
< =2.5 | 227 (17) | 157 (69) | 70 (31) | |
> 2.5 | 230 (18) | 127 (55) | 103 (45) | |
Missing | 637 (49) | 409 (64) | 264 (41) | |
Duration of HCV treatment in weeks | <0.0001 | |||
< =24 | 496 (38) | 390 (79) | 106 (21) | |
24-48 | 437 (33) | 242 (55) | 195 (45) | |
> 48 | 376 (29) | 187 (50) | 189 (50) | |
Calendar year of start HCV treatment | <0.0001 | |||
< =2003 | 266 (20) | 201 (76) | 65(24) | |
2003–2006 | 421 (32) | 258 (61) | 163 (39) | |
> =2006 | 622 (48) | 360 (58) | 262 (42) | |
cART regimen | 0.003 | |||
PI | 158 (12) | 104 (66) | 54 (34) | |
Boosted PI | 444 (34) | 296 (67) | 148 (33) | |
NNRTI | 284 (22) | 154 (54) | 130 (46) | |
PI + NNRTI | 50 (6) | 35 (70) | 15 (30) | |
No PI and/or NNRTI | 131 (10) | 90 (69) | 41 (31) | |
no cART | 242 (18) | 140 (58) | 102 (42) | |
Backbone | <0.0001 | |||
Start after HCV treatment | 242 (18) | 140 (58) | 102 (42) | |
ABC + 3TC | 189 (14) | 117 (62) | 72 (38) | |
AZT + 3TC | 140 (11) | 99 (62) | 41 (29) | |
FTC + TDF | 262 (20) | 147 (56) | 115 (44) | |
TDF + 3TC | 130 (10) | 68 (52) | 62 (48) | |
TDF + ABC | 44 (3) | 27 (61) | 17 (39) | |
d4T + 3TC | 90 (7) | 68 (76) | 22 (24) | |
other | 212 (16) | 153 (72) | 59 (28) | |